Display options
Cite
Kiddie MA, Kaye CM, Turner P, et al. The influence of urinary pH on the elimination of mexiletine. Br J Clin Pharmacol. 1974;1(3):229-32doi: 10.1111/j.1365-2125.1974.tb00241.x.
Kiddie, M. A., Kaye, C. M., Turner, P., & Shaw, T. R. (1974). The influence of urinary pH on the elimination of mexiletine. British journal of clinical pharmacology, 1(3), 229-32. https://doi.org/10.1111/j.1365-2125.1974.tb00241.x
Kiddie, M A, et al. "The influence of urinary pH on the elimination of mexiletine." British journal of clinical pharmacology vol. 1,3 (1974): 229-32. doi: https://doi.org/10.1111/j.1365-2125.1974.tb00241.x
Kiddie MA, Kaye CM, Turner P, Shaw TR. The influence of urinary pH on the elimination of mexiletine. Br J Clin Pharmacol. 1974 Jun;1(3):229-32. doi: 10.1111/j.1365-2125.1974.tb00241.x. PMID: 22454952; PMCID: PMC1402565.
Copy Download .nbib Format: NLM
Share it on

Br J Clin Pharmacol. 1974 Jun;1(3):229-32. doi: 10.1111/j.1365-2125.1974.tb00241.x.

The influence of urinary pH on the elimination of mexiletine.

British journal of clinical pharmacology

M A Kiddie, C M Kaye, P Turner, T R Shaw

Affiliations

  1. Department of Clinical Pharmacology, St Bartholomew's Hospital, London.

PMID: 22454952 PMCID: PMC1402565 DOI: 10.1111/j.1365-2125.1974.tb00241.x

Abstract

1 The plasma elimination half-life of mexiletine was measured in four subjects when the urine was rendered (a) acidic and (b) alkaline. 2 Urinary acidification (pH 5.0) was associated with a plasma elimination half-life of 2.8 h and 57.5% of the intravenous dose was excreted in the urine within 48 hours. When the urine was alkaline (pH 8.0) the half-life increased to 8.6 h with negligible amounts of drug appearing in the urine. 3 Urinary pH varies widely in cardiac patients and should be controlled or monitored to provide better therapeutic precision with mexiletine.

References

  1. Br J Pharmacol. 1973 Sep;49(1):155P-156P - PubMed
  2. Lancet. 1973 Aug 25;2(7826):404-7 - PubMed
  3. N Engl J Med. 1972 Aug 3;287(5):227-31 - PubMed
  4. Br J Pharmacol. 1970 May;39(1):183P-184P - PubMed
  5. J Urol. 1959 Feb;81(2):339-43 - PubMed
  6. Lancet. 1965 Feb 6;1(7380):303 - PubMed
  7. Am J Med. 1964 May;36:743-62 - PubMed
  8. J Clin Invest. 1951 Nov;30(11):1191-9 - PubMed
  9. Br J Pharmacol. 1973 Mar;47(3):674P-675P - PubMed
  10. Am J Med. 1960 Dec;29:1017-33 - PubMed

Publication Types